Pharmaceutical giant Pfizer (NYSE: PFE) is no stranger to investors; the company is a longtime staple in the healthcare industry. It got a lift in late 2020 and in 2021 as one of the COVID-19 vaccine suppliers, but investors seem to have grown bored with Pfizer's story, and the stock is down about 16% since the start of 2022. The thing is, investors shouldn't be so quick to write off Pfizer stock.
The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.
Pfizer (NYSE: PFE) is a 173-year-old company with a huge portfolio of products. This year, Pfizer has dropped about 16%, in line with the S&P 500. In fact, there are three reasons Pfizer stock could crush the broader market in 2023.